About Us
Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential.
The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).
-
Regulatory December 22, 2025Report from Extraordinary General Meeting in Vivesto AB
-
Non Regulatory December 16, 2025Vivesto signs Liberi Group to accelerate partnering activities for Paccal Vet and Cantrixil programs
-
Non Regulatory November 24, 2025Vivesto holds a live-streamed business update today November 24
Interim Report Q3 2025 (in Swedish)
Vivesto published its Q3 report for 2025 on November 20, 2025, at 08.00 am CET.